Drug resistant HIV

British Medical Journal

Volumn 334, Issue 7604, 2007, Pages 1124-1125

  Hatano, Hiroyu ^a   Deeks, Steven G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; EFAVIRENZ; ELVITEGRAVIR; ETRAVIRINE; GS 9137; INTEGRASE INHIBITOR; MARAVINOC; MK 0518; NEVIRAPINE; RALTEGRAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE;

CHRONIC DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION; ANTIBIOTIC RESISTANCE; PHARMACEUTICS;

ANTI-HIV AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; PYRIDAZINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 34250205194     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39205.386609.80     Document Type: Editorial

References (10)

1. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transferthat prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50.
2. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, et al. Results from BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 14th conference on retroviruses and opportunistic infections. Los Angeles, CA, 2007. www.retroconference.org/2007/.
3. Steigbigel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, et al. Results from BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 14th conference on retroviruses and opportunistic infections. Los Angeles, CA, 2007. www.retroconference.org/2007/.
4. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004;20:111-26.
5. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926-30.
6. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44:591-5.
7. GlaxoSmithKline. Statement to HIV patient community: information from GlaxoSmithKline on changes to studies of investigational CCR5 entry inhibitor aplaviroc (GW873140). 15 September 2005. www.hivandhepatitis.com/recent/ad/ 091405a.html.
8. Lalezari J, Goodrich I, DeJesus E, Lampiris H, Gulick R, Saag M, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ARV-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: Program and abstracts of the 14th conference on retroviruses and opportunistic infections. Los Angeles, CA, 2007. www.retroconference.org/2007/.
9. Nelson M, Fatkenheuer G, Konourina I, Lazzarin A, Clumeck N, Horban A, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ARV-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. In: Program and abstracts of the 14th conference on retroviruses and opportunistic infections. Los Angeles, CA, 2007. www.retroconference.org/2007/.
10. Cohen C, Steinhart CR, Ward DJ, Ruane P, Vingerhoets J, Peeters M, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. In: Program and abstracts of the XVI international AIDS conference. Toronto, Canada, 2006.